Circulating Tumor Cell (CTC) Diagnostics: Technologies and Global Markets

Circulating Tumor Cell (CTC) Diagnostics: Technologies and Global Markets

Report Scope:

The scope of this study involves clinical testing, prognostic and monitoring markets for CTCs in cancer. The report also includes the clinical research segment as well as currently approved CTC tests and their markets. The regulatory environment, current technologies, new technologies, cancer incidence, market projections and market share, along with the latest trends and new developments in this area, are included to support the clinical testing market.

Based on cancer type, the market for circulating tumor cells diagnostics is segmented into breast cancer, colorectal cancer and prostate cancer.

Based on technology, the market for circulating tumor cells diagnostics is segmented into CTC enrichment and detection, CTC direct detection and CTC analysis.

Based on application, the market for circulating tumor cells diagnostics is segmented into clinical/liquid biopsy and research.

The report discusses the qualitative and quantitative factors influencing market growth. Market drivers, restraints and opportunities are discussed in the report.

This report discusses some of the major drivers and restraints in the market for circulating tumor cells diagnostics, and it surveys the competitive landscape as well as the key players’ strategies and performances. The discussion is focused on the major market players, trends in product launches, collaborations, and mergers and acquisitions. The report also includes company profiles of major vendors that include a company overview, key product offerings, financial statistics and recent developments. The report provides insights on market shares and upcoming regional demand for circulating tumor cells diagnostics.

Some of the major market players discussed in the report are Qiagen N.V., Biocept Inc., Greiner Bio One International GmbH, Precision Medicine Group LLC and Menarini Silicon Biosystems. For market estimates, data have been provided for the 2020 as the base year, with forecasts for 2021 through 2026. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.

Report Includes:

- 24 data tables and 49 additional tables
- An up-to-date review and analysis of the global markets for circulating tumor cell (CTC) diagnostics
- Analyses of the global market trends, with data from 2019-2021, and projections of compound annual growth rates (CAGRs) through 2026
- Highlights of the upcoming market opportunities in the CTC diagnostics industry, and areas of focus to forecast this market into various segments and sub-segments
- Evaluation and forecast the global CTC diagnostics market size, forecasted growth trends, and corresponding market share analysis by cancer type, technology, application, and region
- In-depth information concerning market drivers and challenges, latest technologies, breakthrough innovations, costs and benefits of CTC enrichment techniques, regulatory concerns, and clinical trials
- Statistical information (facts and figures) on cancer incidence and prevalence, global cancer related deaths, and new cases of cancer by type in the United States
- Review of recent industry trends, value chain analysis, competitive landscape, and COVID-19 implications within the marketplace
- Descriptive company profiles of the leading global players, including Bio-Techne Corp., Biocept Inc., Greiner Bio-One International GmbH, Precision Medicine Group LLC, Menarini Silicon Biosystems, and Qiagen N.V.

Companies Mentioned

BIO-TECHNE CORP. (ADVANCED CELL DIAGNOSTICS INC.)
BIOCEPT, INC.
BIOFLUIDICA
CREATV MICROTECH INC.
FLUXION BIOSCIENCES, INC.
GREINER BIO-ONE INTERNATIONAL GMBH
IKONISYS, INC.
IVDIAGNOSTICS, INC.
MENARINI SILICON BIOSYSTEMS (FORMERLY VERIDEX LLC)
MILTENYI BIOTEC
PRECISION MEDICINE GROUP LLC
QIAGEN N.V.
RARECELLS, INC.
SCREENCELL
STEMCELL TECHNOLOGIES INC.